We are live on ! Find out more

Novartis

NVS

Market cap $306B

162.23 USD

+0.30

0.19%

At close Updated Nov 6, 3:05 PM EST

1 day

0.19%

5 days

1.05%

1 month

15.23%

3 months

5.2%

6 months

9.35%

Year to date

17.1%

1 year

28.17%

5 years

94.94%

10 years

155.36%

About: Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.

Employees: 75,267

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 34.3%

Neutral 22.5%

Negative 43.1%

The Motley Fool

Novartis: 3 Key Takeaways for Long-Term Investors

Novartis raised full-year 2026 core operating income guidance after 4% sales growth. Rhapsido peak sales guidance increased to over $4 billion in combined indications.

Novartis: 3 Key Takeaways for Long-Term Investors

Zacks Investment Research

3 Stocks to Watch Following Guidance Upgrades

The Q3 earnings cycle continues to roll along, with several healthcare companies delivering positive results and raising their outlooks as a result.

3 Stocks to Watch Following Guidance Upgrades

BioArctic collaborator Novartis terminates agreement

STOCKHOLM, Nov. 2, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that Novartis Pharma AG has notified BioArctic that it has decided to terminate the Option, Collaboration and License Agreement entered into in August 2025 to explore a potential new treatment combining BioArctic's proprietary BrainTransporter™ technology with an undisclosed Novartis proprietary antibody. The termination is the result of a Novartis decision to discontinue the program, unrelated to BioArctic's BrainTransporter technology.

BioArctic collaborator Novartis terminates agreement

6 dividend stocks for investors who want to cut their exposure to the S&P 500

Novartis, Mitsubishi and Canadian Natural are examples of companies in developed markets outside the U.S. that pass screens for high dividend yields and low volatility for prices and earnings.

6 dividend stocks for investors who want to cut their exposure to the S&P 500

Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target

The recent failure of a Novartis experimental heart drug in a large trial raised questions among cardiologists and investors about the widely held idea tha

Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target

Novartis: Q3 2026 Earnings Confirm 'Hold' Recommendation Based On Balanced Approach

Novartis is rated Hold, with a 12-month price target of $141.81, implying a 12.0% downside from the current share price. My model indicates near-term pressure on selected products, while projected pipeline revenue may support growth over the longer term. NVS trades at a discount to peers on forward P/E but at a premium on EV/EBITDA, producing mixed relative valuation signals.

Novartis: Q3 2026 Earnings Confirm 'Hold' Recommendation Based On Balanced Approach

Zacks Investment Research

All You Need to Know About Novartis (NVS) Rating Upgrade to Buy

Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Novartis (NVS) Rating Upgrade to Buy

Zacks Investment Research

Why Novartis (NVS) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Novartis (NVS) is a Top Momentum Stock for the Long-Term

A pharma giant is moving past one patent cliff — but another is already looming

Novartis CEO Vas Narasimhan told CNBC on Tuesday that its drug remibrutinib could become "one of our largest medicines in history." But analysts slashed the peak sales forecast for the drug after a late-stage clinical trial for patients with relapsing multiple sclerosis, while reaching its primary endpoint, appeared worse than expected.

A pharma giant is moving past one patent cliff — but another is already looming

Novartis AG (NVS) Q3 2026 Earnings Call Transcript

Novartis AG ( NVS ) Q3 2026 Earnings Call October 27, 2026 8:00 AM EDT Company Participants Isabella Zinck - Investor Relations Manager Vasant Narasimhan - Chief Executive Officer Mukul Mehta - Chief Financial Officer Conference Call Participants Sachin Jain - BofA Securities, Research Division James Gordon - Barclays Bank PLC, Research Division Florent Cespedes - ODDO BHF Corporate & Markets, Research Division Graham Glyn Parry - Citigroup Inc., Research Division Kerry Holford - Joh. Berenberg, Gossler & Co. KG, Research Division Steve Scala - TD Cowen, Research Division James Quigley - Goldman Sachs Group, Inc., Research Division Trung Huynh - RBC Capital Markets, Research Division Thibault Boutherin - Morgan Stanley, Research Division Matthew Weston - UBS Investment Bank, Research Division Peter Verdult - BNP Paribas, Research Division Michael Leuchten - Jefferies LLC, Research Division Richard Vosser - JPMorgan Chase & Co, Research Division Urban Fritsche - Zürcher Kantonalbank, Research Division Seamus Fernandez - Guggenheim Securities, LLC, Research Division Presentation Isabella Zinck Investor Relations Manager Hi, everyone, and welcome to our Q3 earnings call.

Novartis AG (NVS) Q3 2026 Earnings Call Transcript

See News Rankings

Price charts implemented using Lightweight Charts™